FDA 513(g) Provider Directory: Compare +50 Classification Support Providers

If your team is uncertain about product code, regulation number, device type, or likely pathway, a 513(g) Request for Information can reduce expensive regulatory drift. This directory is designed for medical device teams that need to compare providers based on execution quality, not just quote speed.

What a Strong 513(g) Provider Should Actually Deliver

Many teams buy 513(g) support expecting a simple opinion letter. In practice, quality providers build a full argument package: intended use clarity, technology characterization, prior art mapping, and reasoned pathway recommendation. Under section 513(g) of the FD&C Act, FDA responds with its views based on submitted information, but that response quality depends heavily on how the question is framed and what technical context is provided. Weak framing can trigger ambiguous responses that still leave teams unsure whether to pursue 510(k), De Novo, PMA, or a non-device route.

A high-quality provider will do more than cite a regulation number. They should separate "classification confidence" from "submission readiness." A team may have high confidence in probable class while still lacking the bench, software, biocompatibility, or labeling evidence needed for the eventual marketing submission. The best providers make those downstream gaps visible early so you can avoid wasting one or two quarters on the wrong workstream. For operational planning, this distinction is usually worth far more than the consulting fee itself.

Because 513(g) work sits upstream of formal premarket review, providers should also be explicit about uncertainty handling. You want structured language around assumptions, probability-weighted alternatives, and trigger conditions for escalation to Q-Sub. If a provider presents a single pathway as guaranteed without articulating evidence dependencies, that is a warning sign. In mature regulatory operations, uncertainty is managed with transparent assumptions, not hidden.

Directory Segments: Choose by Team Need

Provider Evaluation Criteria (Practical Scorecard)

• Classification methodology: Do they show a repeatable method for mapping intended use, technology characteristics, and risk profile to likely class and controls?
• Regulatory writing quality: Can they convert technical details into concise regulatory arguments that an FDA reviewer can process quickly?
• Device-family depth: Have they supported products in your exact diagnostic, therapeutic, implantable, software, or accessory segment?
• Assumption transparency: Are alternative outcomes and decision triggers documented in writing?
• Handoff quality: Do they deliver reusable artifacts your team can carry into Q-Sub, 510(k), or De Novo?
• Timeline realism: Are milestones tied to evidence readiness, not just calendar promises?
• Cost clarity: Are scope boundaries explicit, especially for revisions after new test data or intended use changes?

How to Compare Providers Without Slowing the Program

Most teams evaluate providers by biography and hourly rate. That creates expensive blind spots. A better approach is to score prospective partners against a small set of simulated classification scenarios before contracting. Ask each provider to explain how they would treat one likely predicate, one borderline predicate, and one high-risk claim in your labeling draft. The quality of that reasoning predicts project outcomes far better than a generic capabilities slide.

Second, separate advisory work from writing deliverables. Many providers can discuss pathway options, but fewer can produce coherent, submission-ready narratives your internal team can directly reuse. Require a sample output format up front: executive memo, evidence matrix, open questions register, and next-step plan. This protects you from paying twice when downstream teams must rebuild everything.

Third, force milestone definitions around verifiable outputs rather than vague "strategic support" phases. Milestones should include a signed-off intended use statement, draft classification rationale, unresolved issue log, and recommended escalation point. If these are not clearly tied to payment stages, project drift is likely. High-functioning teams keep vendor success criteria objective and artifact-based.

Use These 513(g) Utilities Before You Select a Provider

Cross-Linking to Adjacent 510(k) Planning Pages

513(g) work should not live in isolation. A classification answer only creates value when connected to execution artifacts. If your team is also planning a 510(k), review the 510(k) checklist, timeline assumptions in fees and timeline planning, and workflow guidance in the eSTAR guide. If you are balancing consultant usage versus in-house execution, the consultant alternative page explains when hybrid models perform best.

For software-heavy products, classification quality also depends on clear software and cybersecurity framing. Before engaging providers, align internal teams on your software statement of function, user population, and risk controls so the provider receives stable inputs. Unstable inputs are the most common cause of late-stage rework in 513(g) projects.

References

• FDA and Industry Procedures for Section 513(g) Requests for Information
• 21 CFR Part 807, Subpart E (Premarket Notification)
• FDA Q-Submission Program
• FDA Device Advice: How to Study and Market Your Device